33 unknown, 18 recruiting, 14 completed, 8 not yet recruiting. 27 Phase 2, 14 Phase 3, 13 Not applicable, 4 Phase 4, 2 Phase 1.
Follow Taizhou Hospital: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tobramycin Nebulization to Prevent Multidrug-Resistant Ventilator-Associated Pneumonia Tobramycin inhalation solution, 0.9% Sodium Chloride Placebo - Pneumonia, Ventilator-Associated | Phase 4 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 574 | 2026-10-07 | 2026-10-02 |
| Study on the Impact of Decolonization Treatment of Pneumocystis Jirovecii on the Frequency of Acute Exacerbation in COPD Trimethoprim-Sulfamethoxazole (TMP-SMX), Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Not applicable | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 630 | 2026-07-01 | 2026-06-24 |
| Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG) Intervention for Venetoclax, Intervention for Homoharringtonine, Intervention for Azacitidine - Acute Myeloid Leukemia (AML) | Phase 2 | Not yet recruiting | First People's Hospital of Hangzhou | 61 | 2026-03-31 | 2026-04-02 |
| Fertility Outcomes In Young Breast Cancer Patients And Their Prognosis And Offspring Health Prognosis, Fertility | Enrolling by invitation | Taizhou Hospital | 2000 | 2026-01-01 | 2026-01-29 | |
| Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen Fosaprepitant, Tropisetron, Olanzapine - Multiple Myeloma | Phase 3 | Recruiting | The Affiliated People's Hospital of Ningbo University | 92 | 2025-10-31 | 2026-02-17 |
| Risankizumab for Fibrostenotic Crohn's Disease Treatment Ustekinumab, Risankizumab - Crohn Disease, Crohn Disease and Ulcerative Colitis | Phase 3 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 260 | 2025-10-20 | 2025-09-16 |
| Butylphthalide for Cognitive Impairment in Elderly Patients With Focal Epilepsy Butylphthalide, Placebo - Focal Epilepsy, Cognitive Impairment | Phase 4 | Recruiting | First Affiliated Hospital of Wenzhou Medical University | 220 | 2025-09-01 | 2025-09-25 |
| Enhancing Critical Thinking Competency and Nursing Quality in Critically Ill Patient Care Conventional group, evidence-based nursing group - Evidence-Based Nursing, Critically Ill Patient | Not applicable | Completed | Taizhou Hospital | 84 | 2025-05-25 | 2026-03-19 |
| Comparison of Sequential to Initial Combination Therapy in PAH Tadalafil, Ambrisentan, Ambrisentan mimic - Pulmonary Arterial Hypertension (PAH) | Not applicable | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 376 | 2025-05-14 | 2025-07-29 |
| Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma orelabrutinib combined with the Pola-R-CHP regimen - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 48 | 2025-05-05 | 2025-08-19 |
| Establishment and Clinical Application of Breast Cancer Risk Prediction Model Based on Traditional Chinese Medicine Four Diagnostic Instruments and Ultrasound Diagnosis of Breast Cancer by Traditional Chinese Medicine Four Examinations, Ultrasound diagnosis of breast cancer - Breast Cancer Screening | Not yet recruiting | Taizhou Hospital | 1500 | 2025-04-26 | 2025-03-30 | |
| Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma orelabrutinib combined with rituximab regimen - Marginal Zone Lymphoma(MZL) | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 51 | 2025-03-11 | 2025-06-15 |
| SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer Experimental, Control - Locally Advanced Rectal Cancer (LARC) | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 116 | 2025-01-06 | 2026-01-14 |
| Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC befotertinib - NSCLC (Non-small Cell Lung Cancer) | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 78 | 2024-10-01 | 2025-03-07 |
| Prediction of Stroke Risk in Patients with Atrial Fibrillation Based on Chest CT Images observational study - Atrial Fibrillation (AF), Ischemic Stroke | Unknown | First Affiliated Hospital of Zhejiang University | 1500 | 2024-09-23 | 2024-09-25 | |
| Efficacy and Safety of TJ0113 Capsule in Patients With Parkinson's Disease TJ0113 200mg, TJ0113 400mg, Placebo - Parkinson Disease | Phase 2 | Completed | Second Affiliated Hospital, Zhejiang University, School of Medicine | 149 | 2024-09-18 | 2026-01-16 |
| Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma Etoposide, Cytarabine, PEG-rhG-CSF - Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization | Phase 3 | Recruiting | The Affiliated People's Hospital of Ningbo University | 99 | 2024-08-01 | 2025-12-04 |
| Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients Etoposide, Cytarabine, Pegfilgrastim - Multiple Myeloma, Hematopoietic Stem Cell Mobilization | Phase 3 | Recruiting | The Affiliated People's Hospital of Ningbo University | 99 | 2024-08-01 | 2024-07-25 |
| Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy - Breast Cancer | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 200 | 2024-07-25 | 2025-12-19 |
| Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell Toripalimab plus Anlotinib, Toripalimab - SCLC, Maintenance Treatment | Phase 3 | Not yet recruiting | Taizhou Hospital | 136 | 2024-07-01 | 2024-06-04 |
Showing 20 of 76. Sign in to see all of them.
Stroke (7) · Breast Neoplasms (6) · Ischemic Stroke (5) · Carcinoma, Non-Small-Cell Lung (2) · Cognitive Dysfunction (2) · Emergencies (2) · Gastritis (2) · Hematologic Neoplasms (2) · Inflammation (2) · Lymphedema (2) · Lymphoma, Large B-Cell, Diffuse (2) · Multiple Myeloma (2) · Nasopharyngeal Carcinoma (2) · Pulmonary Disease, Chronic Obstructive (2) · Asthma (1)
Etoposide (3) · Granulocyte Colony-Stimulating Factor (3) · Radiotherapy (3) · toripalimab (3) · Azacitidine (2) · Cytarabine (2) · Fingolimod Hydrochloride (2) · Neoadjuvant Therapy (2) · Observation (2) · Ultrasonography (2) · anlotinib (2) · pegylated granulocyte colony-stimulating factor (2) · sintilimab (2) · venetoclax (2) · 1-(1-glycero)dodeca-1,3,5,7,9-pentaene (1)
China (68)
Min Lou, PhD (3) · Haihua Yang, MD (2) · Jian-an Wang, MD, PhD (2) · Mao Zhang, MD (2) · Peipei Ye (2) · Xin-Wu Cui, PhD,MD (2) · Yi Luo, M.D. (2) · YiYang Zhu, MD (2) · You-Bin Deng, PhD,MD (2) · Bo Hu, Dr. or PhD. (1) · Chao Zhou, MD. (1) · Dongqing Lv, MD (1) · Feilin Cao, MD (1) · Feilin Cao, Master (1)
PMID 17057569, PMID 20485617, PMID 22459631, PMID 24034748, PMID 24165758, PMID 24907633, PMID 25360316, PMID 26104794, PMID 27184656, PMID 28071987, PMID 28992680, PMID 29681007, PMID 30089078, PMID 32395294, PMID 32877795, PMID 33593763, PMID 34160577, PMID 34268122, PMID 34702747, PMID 35066633, PMID 36404303, PMID 36533622, PMID 38485149, PMID 38787930, PMID 39333988, PMID 39922675, PMID 40040869, PMID 40178527, PMID 41780001